- Home
- AKRO vs CMRE Comparison
AKRO vs CMRE Comparison
Compare AKRO & CMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- CMRE
- Stock Information
- Founded
- AKRO 2017
- CMRE 1974
- Country
- AKRO United States
- CMRE Monaco
- Employees
- AKRO N/A
- CMRE N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- CMRE Marine Transportation
- Sector
- AKRO Health Care
- CMRE Consumer Discretionary
- Exchange
- AKRO Nasdaq
- CMRE Nasdaq
- Market Cap
- AKRO 2.0B
- CMRE 1.9B
- IPO Year
- AKRO 2019
- CMRE 2010
- Fundamental
- Price
- AKRO $28.08
- CMRE $13.49
- Analyst Decision
- AKRO Strong Buy
- CMRE Hold
- Analyst Count
- AKRO 8
- CMRE 2
- Target Price
- AKRO $46.83
- CMRE $13.50
- AVG Volume (30 Days)
- AKRO 594.3K
- CMRE 242.2K
- Earning Date
- AKRO 02-27-2025
- CMRE 02-05-2025
- Dividend Yield
- AKRO N/A
- CMRE 3.42%
- EPS Growth
- AKRO N/A
- CMRE N/A
- EPS
- AKRO N/A
- CMRE 3.01
- Revenue
- AKRO N/A
- CMRE $2,030,338,000.00
- Revenue This Year
- AKRO N/A
- CMRE $19.29
- Revenue Next Year
- AKRO N/A
- CMRE N/A
- P/E Ratio
- AKRO N/A
- CMRE $4.27
- Revenue Growth
- AKRO N/A
- CMRE 58.37
- 52 Week Low
- AKRO $15.32
- CMRE $10.14
- 52 Week High
- AKRO $37.00
- CMRE $17.58
- Technical
- Relative Strength Index (RSI)
- AKRO 41.87
- CMRE 58.09
- Support Level
- AKRO $27.45
- CMRE $12.59
- Resistance Level
- AKRO $28.76
- CMRE $13.02
- Average True Range (ATR)
- AKRO 1.49
- CMRE 0.32
- MACD
- AKRO -0.12
- CMRE 0.09
- Stochastic Oscillator
- AKRO 17.98
- CMRE 99.44
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
About CMRE Costamare Inc. $0.0001 par value
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and among others. Costamare provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.